• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Shaping the future of cardiometabolic innovation: advances and opportunities.

作者信息

Clemmensen Christoffer, Gerhart-Hines Zachary, Schwartz Thue W, Zierath Juleen R, Sakamoto Kei

机构信息

Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Department of Molecular Medicine and Surgery, Section for Integrative Physiology, Karolinska Institutet, Stockholm, Sweden.

出版信息

Nat Metab. 2025 Jul 11. doi: 10.1038/s42255-025-01343-5.

DOI:10.1038/s42255-025-01343-5
PMID:40646330
Abstract
摘要

相似文献

1
Shaping the future of cardiometabolic innovation: advances and opportunities.塑造心血管代谢创新的未来：进展与机遇
Nat Metab. 2025 Jul 11. doi: 10.1038/s42255-025-01343-5.
2
Shaping the Future of "Cardio-Kidney-Metabolic" Health: Insights From The Texas Heart Institute's 2024 Cardiometabolic Syndrome Conference.塑造“心肾代谢”健康的未来：来自德克萨斯心脏研究所2024年心脏代谢综合征会议的见解
Tex Heart Inst J. 2025 Jan 23;52(1):e248536. doi: 10.14503/THIJ-24-8536. eCollection 2025 Jan-Jun.
3
Chrononutrition and Cardiometabolic Health: An Overview of Epidemiological Evidence and Key Future Research Directions.时间营养与心脏代谢健康：流行病学证据概述及未来主要研究方向。
Nutrients. 2024 Jul 19;16(14):2332. doi: 10.3390/nu16142332.
4
What are the greatest opportunities for innovation to improve access to and quality of palliative care services to children? A qualitative interview study.改善儿童姑息治疗服务的可及性和质量，创新的最大机遇有哪些？一项定性访谈研究。
BMC Palliat Care. 2025 Jul 2;24(1):184. doi: 10.1186/s12904-025-01837-9.
5
The Impact of Early-Life Growth on Long-Term Cardiometabolic and Neurocognitive Outcomes in High-Income Countries: A Neglected Public Health Problem.高收入国家早期生长对长期心脏代谢和神经认知结局的影响：一个被忽视的公共卫生问题。
Nutr Rev. 2025 Jul 9. doi: 10.1093/nutrit/nuaf098.
6
The contribution of private and public centres to innovation in fertility care: acknowledging the past and preserving the future.私立和公立机构对生育护理创新的贡献：铭记过去，守护未来。
Reprod Biomed Online. 2025 May 15;51(4):105052. doi: 10.1016/j.rbmo.2025.105052.
7
Evaluation of the Patient Innovation Partner Role: Perceived Benefits, Structures, Supports, and Recommendations for Lived Experience Engagement in Healthcare Innovation Teams.患者创新伙伴角色评估：医疗创新团队中参与真实体验的感知益处、结构、支持及建议
Health Expect. 2025 Apr;28(2):e70194. doi: 10.1111/hex.70194.
8
Cultural Tailoring and Implementation Science for Cardiometabolic Interventions in Asian Americans: A Systematic Review.亚裔美国人心脏代谢干预的文化调适与实施科学：系统评价。
Nurs Open. 2024 Nov;11(11):e70083. doi: 10.1002/nop2.70083.
9
Cardiometabolic Risk Markers for Aboriginal and Torres Strait Islander Children and Youths: A Systematic Review of Data Quality and Population Prevalence.原住民和托雷斯海峡岛民儿童和青少年的心脏代谢风险标志物：数据质量和人群流行率的系统评价。
Int J Environ Res Public Health. 2023 Jun 26;20(13):6228. doi: 10.3390/ijerph20136228.
10
Balancing Surgical Innovation and Risk: A Narrative Review of Emerging Technologies, Regulation, and Global Access.平衡手术创新与风险：新兴技术、监管及全球可及性的叙述性综述
Cureus. 2025 Jul 14;17(7):e87957. doi: 10.7759/cureus.87957. eCollection 2025 Jul.

本文引用的文献

1
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.替尔泊肽与司美格鲁肽治疗肥胖症的比较
N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11.
2
SnapShot: Brain-targeting anti-obesity medications.简讯：脑靶向抗肥胖药物
Cell Metab. 2025 Mar 4;37(3):790-790.e1. doi: 10.1016/j.cmet.2025.02.006.
3
The weight-loss drugs being tested in 2025: will they beat Ozempic?2025年正在进行测试的减肥药物：它们会击败奥泽米皮克吗？
Nature. 2025 Feb;638(8051):591-592. doi: 10.1038/d41586-025-00376-w.
4
NK2R control of energy expenditure and feeding to treat metabolic diseases.NK2R 控制能量消耗和摄食以治疗代谢疾病。
Nature. 2024 Nov;635(8040):987-1000. doi: 10.1038/s41586-024-08207-0. Epub 2024 Nov 13.
5
Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.现实世界中司美格鲁肽用于体重管理：患者特征和剂量滴定-丹麦队列研究。
Diabetes Care. 2024 Oct 1;47(10):1834-1837. doi: 10.2337/dc24-1082.
6
The benefits of GLP-1 drugs beyond obesity.胰高血糖素样肽-1（GLP-1）药物在治疗肥胖症之外的益处。
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
7
GLP-1-directed NMDA receptor antagonism for obesity treatment.GLP-1 靶向 NMDA 受体拮抗剂治疗肥胖。
Nature. 2024 May;629(8014):1133-1141. doi: 10.1038/s41586-024-07419-8. Epub 2024 May 15.
8
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.三重激素受体激动剂 Retatrutide 治疗肥胖症的 2 期临床试验
N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.
9
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
10
Anti-obesity drug discovery: advances and challenges.抗肥胖药物的发现：进展与挑战。
Nat Rev Drug Discov. 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov 23.